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Abstract
Background: RNA extracted from formalin-fixed paraffin-embedded (FFPE) samples is chemically modified and
degraded, which compromises its use in gene expression studies. Most of the current approaches for RNA quality
assessment are not suitable for FFPE derived RNA.
Results: We have developed a single-tube multiplex endpoint RT-PCR assay specifically designed to evaluate RNA
extracted from FFPE tissues for mRNA integrity and performance in reverse transcription - quantitative real-time
PCR (RT-qPCR) assays. This single-tube quality control (QC) assay minimises the amount of RNA used in quality
control. mRNA integrity and the suitability of RNA for RT-PCR is evaluated by the multiplex endpoint RT-PCR assay
using the TBP gene mRNA as the target sequence. The RT-PCR amplicon sizes, 92, 161, 252 and 300 bp, cover a
range of amplicon sizes suitable for a wide range of RT-qPCR assays. The QC assay was used to evaluate RNA
prepared by two different protocols for extracting total RNA from needle microdissected FFPE breast tumour
samples. The amplification products were analysed by gel electrophoresis where the spectrum of amplicon sizes
indicated the level of RNA degradation and thus the suitability of the RNA for PCR. The ability of the multiplex
endpoint RT-PCR QC assay to identify FFPE samples with an adequate RNA quality was validated by examining the
Cq values of an RT-qPCR assay with an 87 bp amplicon.
Conclusions: The multiplex endpoint RT-PCR assay is well suited for the determination of the quality of FFPE
derived RNAs, to identify which RT-PCR assays they are suitable for, and is also applicable to assess non-FFPE RNA
for gene expression studies. Furthermore, the assay can also be used for the evaluation of RNA extraction protocols
from FFPE samples.
Background
Formalin-fixed paraffin-embedded (FFPE) tissue samples
are routinely used for diagnosis of disease. There is
increasing interest in extracting RNA from these sam-
ples as the large numbers of archival FFPE samples con-
stitute an invaluable resource for the investigation of
diagnostic, prognostic or predictive disease associated
alterations in gene expression (reviewed in [1]). Further-
more, these often represent the only diagnostic material
available.
However, RNA extracted from FFPE specimens is
extensively degraded and chemically modified, which
compromises its use in PCR based applications
(reviewed in [2]). Degradation of RNA is influenced by
the time and storage conditions between sample collec-
tion and formalin fixation, the fixation process, and the
conditions and length of the subsequent storage [3].
Chemical modifications of RNA are caused by formalde-
hyde and result in the addition of mono-methylol
groups to RNA bases and subsequently in the formation
of methylene bridges between RNA bases [4], and
RNA-protein cross-links [5]. The addition of the mono-
methylol group is in principal reversible, but a consider-
able amount is still present after RNA purification [4].
Whereas the extent of chemical modifications of the
RNA initially limits the PCR amplification size, with
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determining the size of amplifiable PCR fragments [3].
The RNA fragment sizes from FFPE tissue are usually
less than 300 bp and may be less than 100 bp [3,6-8].
The quality of the extracted RNA is a critical factor for
both microarray based and reverse transcription - quanti-
tative real-time PCR (RT-qPCR) gene expression experi-
ments. Microarray based approaches are more sensitive
to RNA degradation and chemical modifications [2],
which potentially influence the gene expression data [9].
RT-qPCR assays are less affected by RNA degradation
and chemical modifications especially when the RT-qPCR
amplicon size is less than 100 bp [10]. It is nevertheless an
essential prerequisite to characterise the quality of the
extracted RNA prior to its use in a gene expression study
to evaluate its suitability for the planned application and
to minimise data misinterpretation [11,12].
RNA quality is often defined in terms of RNA purity
and RNA integrity. RNA purity is spectrophotometri-
cally determined by the A260/A280 and A260/A230 absor-
bance ratios [13-15]. Both ratios are used to evaluate
the level of contaminants such as proteins and residual
organic compounds present in a RNA sample. These
values provide no information about RNA degradation
and amplifiable PCR amplicon sizes.
RNA integrity evaluates the level of RNA degradation
and several methods have been developed for RNA
integrity assessment. Two of the most commonly used
approaches are suitable for assessing moderately
degraded RNA but not highly degraded RNA.
The first approach investigates the ratio between the
28S and 18S ribosomal RNA bands and presumes that
the integrity of ribosomal RNA reflects the integrity of
mRNA [16,17]. The typical RNA fragment sizes of less
than 300 bp make this methodology unsuitable for highly
degraded RNA from FFPE samples [8]. Furthermore, this
approach does not take chemical modifications of the
RNA into account and provides no information on how
the extracted RNA performs in RT-PCR.
The second approach has been adopted from a com-
mon practice in microarray experiments [18] and deter-
mines the mRNA integrity by utilising RT-qPCR assays
to assess the 3’:5’ ratio of a gene target sequence, such as
GAPDH [19] or ACTB [12]. These assays need to reach a
considerable fragment size (up to 1.2 kb) to calculate the
3’:5’ ratio, which makes this methodology unsuitable for
highly degraded RNA from FFPE samples. Moreover, the
3’:5’ assays utilise an oligo-dT primer for cDNA prepara-
tion, which precludes the cDNA obtained from being
used in the majority of RT-PCR assays, an important fac-
tor when the amount of RNA is often limited.
The third approach assesses a range of fragment sizes
generated by (multiplexed) endpoint RT-PCR assays for
certain reference (housekeeping) genes, such as G6PD,
TBP, HPRT and ACTB [3,20-22]. This approach takes
both fragmentation and chemical modifications of the
RNA into account and determines the PCR amplicon
sizes, which might be obtained in a PCR based applica-
tion. When the PCR amplicon sizes cover a range from
less than 100 bp to several hundred base pairs, this
methodology is suitable to assess the extent of the
degradation of RNA extracted from FFPE tissues.
In this study, we sought to combine the best features
of assays from the third approach to develop a readily
performable endpoint RT-PCR assay to assess RNA
extracted from FFPE samples for mRNA integrity and
RNA performance in RT-qPCR assays.
The assay utilises the TBP (TATA box binding pro-
tein) reference gene mRNA as the target sequence. TBP
has been shown to be relatively stably expressed in a
range of tissues [23] and various tumour types (e.g.
[24-29]). Four different amplicon sizes are amplified in
parallel in a single tube from cDNA (multiplexed end-
point RT-PCR assay) to minimise the consumption of
what are often limited amounts of RNA. The amplicon
sizes chosen cover a range of up to 300 bp and are
therefore tailored to the fragment size limitations typi-
cally observed for RNA extracted from FFPE samples
and PCR amplicon sizes usually used for the vast major-
ity of RT-qPCR assays.
Our improved multiplex endpoint RT-PCR assay is a
robust and convenient method which overcomes the
limitations of current approaches for the quality assess-
ment of RNA extracted from FFPE specimens. The
assay has been thoroughly validated by assessing the
quality of 180 RNA samples extracted from FFPE tissues
with an RT-qPCR assay.
Results
Assessment of total RNA yield and purity using optical
density
The amount of total RNA extracted for each of the sam-
ples was measured by a NanoDrop ND-2000 spectro-
photometer and is shown for each sample replicate in
Figure 1. The estimated mean total RNA extracted for
protocol 1 was 2.23 μg (111.5 ng/μL) with values ranging
from 0.24 to 14.24 μg (12.0 to 712.0 ng/μL). For protocol
2, the estimated mean concentration was 2.76 μg
(55.1 ng/μL) with values ranging from 0.12 to 3.61 μg
(2.4 to 72.1 ng/μL).
The corresponding absorbance ratio A260/A280 for
each sample replicate is shown in Figure 1. The mean
A260/A280 ratio for protocol 1 was 1.8 ± 0.2 and for pro-
tocol 2 1.7 ± 0.1. The desired ratio A260/A280 is in the
range of 1.7 to 2.1 and is dependent on the extraction
conditions [30].
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Page 2 of 11The use of the multiplex endpoint RT-PCR for assessment
of mRNA integrity
The integrity of the mRNA extracted from each sample
was assessed by the multiplex endpoint RT-PCR assay
using the TBP (TATA box binding protein) mRNA
(NM_003194) as the target sequence (Figure 2). The
assay was designed to amplify four amplicons of 92, 161,
252 and 300 bp in parallel in a single tube (Figure 3).
T h ea m p l i c o n sw e r ed e s i g n e dt ob ea m p l i f i e df r o m
cDNA but not genomic DNA (Figure 3). This is of par-
ticular importance for assessing cDNA synthesised from
total RNA, which has not been treated with DNase. We
used primer pairs where the primers were in exons
spanning one or more introns (Figure 2). Furthermore,
the primer locations were chosen to exclude known
polymorphic sites from the primer binding sites.
The results for protocols 1 and 2 are summarised in
Figures 4 and 5 for each sample replicate. In general,
the least degraded RNA was extracted from the year
2003 samples for both protocols (Figures 4 and 5). In
addition, the vast majority of sample replicates of both
protocols amplified the 161 bp and 252 bp PCR frag-
ments (Figures 4 and 5, Table 1).
Assessment of mRNA performance by RT-qPCR
The performance of the mRNA extracted from each
sample was assessed by a RT-qPCR assay also using the
TBP mRNA as the target sequence (Figure 2). The RT-
qPCR assay was designed and optimised to be moni-
tored using hydrolysis probes from the Universal Probe
Library (UPL) library in combination with gene-specific
primers [31,32]. The assay amplifies an amplicon of 87
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Figure 1 Assessment of total RNA yield and purity extracted by the two different RNA extraction protocols. The x-axis shows the sample
identification. The y-axis on the left shows the RNA concentration in ng/μL. The RNA concentrations for each of the sample replicates are shown
as groups of three bars. The y-axis on the right shows the absorbance ratio A260/A280. The absorbance ratio A260/A280 for each of the sample
replicates is shown as a scatter graph (■: replicate 1; ▲: replicate 2; ●: replicate 3). Panel A corresponds to protocol 1 (P1) and Panel B
corresponds to protocol 2 (P2). Note that for the RNA concentration, panel A is scaled differently to panel B as the RNA extracted by the two
different RNA extraction protocols was eluted in different final elution volumes.
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Page 3 of 11bp from cDNA using an intron-spanning primer pair.
The quantification cycle (Cq) [33] values obtained for
each sample replicate in the RT-qPCR assay were used
to estimate the quantity of amplifiable template.
Each sample replicate was classified into one of three
different groups based on the Cq values measured (Cq ≤
32.0; 32.1 ≤ Cq ≤ 35.0; 35.1 ≤ Cq ≤ 39.9) (Table 2). The
Cq value is inversely proportional to the number of
amplifiable templates. A Cq value of 35 is generally con-
sidered as the limit for the detection of a single copy
template [34,35]. A Cq value above 35 thus represents
less than one copy template present and can be consid-
ered as background noise of the RT-qPCR assay [35]. A
theoretical Cq value of 32 represents approximately 10
copies of the target template.
Eighty seven percent (78/90) of samples extracted by
protocol 1 and 80% (72/90) of samples isolated by pro-
tocol 2 showed Cq values less than 35.1 for the TBP
RT-qPCR assay (Figures 4 and 5, Table 2). Therefore,
cDNA prepared from RNA extracted with protocol 1
might had slightly more amplifiable templates per sam-
p l ev o l u m et h a nc D N Ap r e p a r e df r o mt o t a lR N A
extracted with protocol 2.
Comparison of the multiplex endpoint RT-PCR and RT-
qPCR assays
The results from the multiplex endpoint RT-PCR assay
were validated by the results obtained from the RT-
qPCR assay and allowed the identification of FFPE sam-
ples with an adequate RNA quality.
300-F 300-R
RT-qPCR-F RT-qPCR-R
161-F 161-R
92-F 92-R
252-F 252-R
E1 E2 E3 E4 E5 E6 E7 E8
Figure 2 Primer placement for the multiplex endpoint RT-PCR and the RT-qPCR assay. Both assays use the TBP mRNA (NM_003194) as the
target sequence. The eight exons are shown as rectangles labelled from E1 to E8. The primer locations are shown as horizontal arrow heads. The
positions of the primers for the multiplex endpoint RT-PCR assay (92-F, 92-R, 161-F, 161-R, 252-F, 252-R, 300-F and 300-R) and for the RT-qPCR
assay (RT-qPCR-F and RT-qPCR-R) are shown. Each primer pair was designed to span at least one intron.
300
252
489/501
404
331
242
1 M W 234567 891 0 M W
161
92
147
110/111
190
67
Figure 3 Assessment of RNA degradation and RNA performance in RT-PCR by the multiplex endpoint RT-PCR assay. The sizes of the
molecular weight markers (MW) are given on the left, whereas the sizes of the TBP amplicons are indicated on the right. Sizes are given in base
pairs. Lane 1 and 10 were loaded with the no template control (NTC). Lane 2 and 9 were loaded with the PCR reaction obtained from a cDNA
mixture synthesised from RNA extracted from different cell lines and serves as positive control, showing all four PCR amplification products of the
expected size. Lane 8 was loaded with the PCR reaction obtained from genomic DNA and served as negative control. Lanes 3 to 7 were loaded
with RT-PCR reactions obtained from cDNAs synthesised from total RNA derived from needle microdissected FFPE breast tumour tissues (Lane 3:
P1-98-05, replicate 1; Lane 4: P1-98-06, replicate 1; Lane 5: P1-98-07, replicate 1; Lane 6: P1-98-08, replicate 1; Lane 7: P1-98-09, replicate 1).
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Page 4 of 11Almost all the samples (135/139) that amplified the
PCR fragments more than 92 bp in the multiplex end-
point RT-PCR assay amplified the 87 bp product at Cq
values less than 35.1 in the RT-qPCR assay consistent
with a greater amount of amplifiable template (Figures 4
and 5, Table 1).
Six percent (10/180) of the samples did not amplify
in the multiplex endpoint RT-PCR assay (Table 1).
Consistent with this, the absence of the 92 bp ampli-
con was associated with late amplification in the RT-
qPCR assay with a Cq value later than 35.0 (Figures 4
and 5, Table 1).
In some cases, stochastic effects due to the very small
number of available templates, can give inconsistent
results; e.g. for one of the replicates of sample P2-08-08,
the 92 bp amplicon did not amplify in the multiplex
endpoint RT-PCR assay but showed a band for the 161
bp product (Figure 5). The other replicates showed a 92
bp band and band sizes up to the 161 bp amplicon,
respectively. All three replicates showed Cq values in the
RT-qPCR assay above 35.0 (Figure 5) indicating that on
average less than one copy of template was present.
We saw no FFPE samples that gave robust amplifica-
tion for the 300 bp amplicon. Forty six percent (41/90)
of the samples prepared by protocol 1 amplified all the
amplicons up to 252 bp in the multiplex endpoint RT-
PCR assay (Figure 4). These samples showed a mean Cq
value in the RT-qPCR assay of 31.5 ± 1.0 with values
ranging from 30.0 to 33.7. For protocol 2, 33% (30/90)
of the samples amplified the amplicons up to 252 bp
and showed a mean Cq v a l u eo f3 1 . 7±0 . 8w i t hv a l u e s
ranging from 31.7 to 33.3 (Figure 5).
Correlations between a longer amplicon size in the
multiplex endpoint RT-PCR assay and the appropriate
Cq value obtained in RT-qPCR were evaluated by calcu-
lating the Spearman correlation coefficient. We found
an inverse correlation for both parameters for protocols
1a n d2[ r(P1) = -0.75, CI (95%) = -0.83 to -0.65 (P <
0.0001, n = 90) and r(P2) = -0.80, CI (95%) = -0.86 to
-0.70 (P < 0.0001, n = 90), respectively]. Thus, a longer
fragment size in the multiplex endpoint RT-PCR assay
was correlated with a smaller Cq value in the RT-qPCR
assay for both total RNA extraction protocols (Figure 6).
Interestingly, both the multiplex endpoint RT-PCR
and the RT-qPCR assay show that the samples prepared
from 2003 performed best during PCR amplification. All
60 samples from 2003 extracted by protocols 1 and 2
amplified PCR amplicons up to 161 bp in the multiplex
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32.6 31.1 31.3 30.8 31.1 30.5 30.5 30.7 33.1 30.9
WϭͲϬϴͲϬϭ WϭͲϬϴͲϬϮ WϭͲϬϴͲϬϯ WϭͲϬϴͲϬϰ WϭͲϬϴͲϬϱ WϭͲϬϴͲϬϲ WϭͲϬϴͲϬϳ WϭͲϬϴͲϬϴW ϭ Ͳ Ϭ ϴ Ͳ Ϭ ϵW ϭ Ͳ Ϭ ϴ Ͳ ϭ Ϭ
ϵϮďƉ
ϭϲϭďƉ
ϮϱϮďƉ
30.8 36.4 36.0 31.9 35.9 32.9 33.0 35.6 33.1 34.0
WϭͲϬϯͲϬϭ WϭͲϬϯͲϬϮ WϭͲϬϯͲϬϯ WϭͲϬϯͲϬϰ WϭͲϬϯͲϬϱ WϭͲϬϯͲϬϲ WϭͲϬϯͲϬϳ WϭͲϬϯͲϬϴW ϭ Ͳ Ϭ ϯ Ͳ Ϭ ϵW ϭ Ͳ Ϭ ϯ Ͳ ϭ Ϭ
Ɖ
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ϮϱϮďƉ
WϭͲϵϴͲϬϭ WϭͲϵϴͲϬϮ WϭͲϵϴͲϬϯ WϭͲϵϴͲϬϰ WϭͲϵϴͲϬϱ WϭͲϵϴͲϬϲ WϭͲϵϴͲϬϳ WϭͲϵϴͲϬϴ WϭͲϵϴͲϬϵ WϭͲϵϴͲϭϬ
ϵϮďƉ
ϭϲϭďƉ
ϮϱϮďƉ
31.7 31.7 32.7 34.8 33.9 31.9 32.8 33.8 33.1 33.8
Figure 4 Comparison of the multiplex endpoint RT-PCR and RT-qPCR assays for protocol 1 (P1). The bottom axis identifies the samples.
The band sizes obtained for each of the sample replicate are shown as bars. The values on the top of the graph provide both the Cq value
measured for each sample replicate in the TBP RT-qPCR assay and the mean Cq value. Symbols are as follows: * indicates a standard deviation
between replicates that is greater than 0.5; ** one out of two replicates amplified.
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Page 5 of 11endpoint RT-PCR assay (Figures 4 and 5). Furthermore, all
of these samples also amplified the 87 bp amplicon with
Cq values less than 35.1 in the RT-qPCR assay (Figures 4
and 5). The lack of correlation between age of the FFPE
samples and RNA quality has been reported previously
[36]. This may be explained by a difference in the proces-
sing of the samples, such as pre-fixation time, fixation
time and storage conditions over the course of time [3,21].
The variation in PCR fragment sizes present in each sam-
ple replicate was also the least in the samples prepared in
year 2003 compared to samples prepared from the years
1998 and 2008, consistent with a minimisation of stochas-
tic effects caused by greater amounts of template. The
effect of sample age needs further investigation.
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Figure 5 Comparison of the multiplex endpoint RT-PCR and RT-qPCR assays for protocol 2 (P2). The bottom axis identifies the samples.
The band sizes obtained for each of the sample replicate are shown as bars. The values on the top of the graph provide both the Cq value
measured for each sample replicate in the TBP RT-qPCR assay and the mean Cq value. Samples labelled with a * symbol indicate a standard
deviation between replicates that is greater than 0.5.
Table 1 Correlation of the multiplex endpoint RT-PCR
and the RT-qPCR assay
Multiplex RT-
PCR
Protocol No. samples in RT-
PCR
No. samples in RT-
qPCR
No
amplification
P1 3/90 (3%) Cq < 35.1 : 0
Cq ≥ 35.1 : 3
P2 7/90 (8%) Cq < 35.1 : 0
Cq ≥ 35.1 : 7
92 bp P1 13/90 (15%) Cq < 35.1 : 5
Cq ≥ 35.1 : 8
P2 18/90 (20%) Cq < 35.1 : 10
Cq ≥ 35.1 : 8
>92 bp P1 74/90 (82%) Cq < 35.1 : 73
Cq ≥ 35.1 : 1
P2 65/90 (72%) Cq < 35.1 : 62
Cq ≥ 35.1 : 3
Table 2 Cq values measured by the RT-qPCR assay
Cq ≤ 32 32.1 ≤ Cq ≤ 35.0 35.1 ≤ Cq ≤ 39.9
P1-08 5 14 11
P1-03 24 6 0
P1-98 7 22 1
P1 (total) 36 42 12
P2-08 4 12 14
P2-03 20 10 0
P2-98 5 21 4
P2 (total) 29 43 18
Samples from years 2008, 2003 and 1998 were analysed by each of the two
protocols. Each sample of protocol 1 (P1) and 2 (P2) was separated into three
groups (based on the Cq value measured for each sample replicate).
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There has been an increasing demand for reliable meth-
ods and protocols for the extraction of RNA from FFPE
tissue sections. The performance of RNA preparation
protocols has improved over the years and specific pro-
tocols for certain RNA downstream applications have
been developed (reviewed in [1,2]).
Despite the improvements in methodologies for
extracting RNA from FFPE specimens, one significant
and challenging problem still remains. The quality of
the extracted RNA is compromised and the degree of
RNA degradation and the extent of chemical modifica-
tions of the RNA may limit its use in downstream appli-
cations. It is therefore critical to assess the RNA quality
at the cDNA stage to identify the RNA preparations
which are suitable for a particular RT-qPCR analysis.
The multiplex endpoint RT-PCR approach used in
this study has been developed and optimised to assess
RNA extracted from FFPE specimens for its use in RT-
qPCR assays. The assay is sensitive to RNA degradation
as well as chemical modifications, which both determine
the length of an amplicon during PCR amplification.
This methodology is similar in principle to one that has
been used extensively in our laboratory for the assess-
ment of DNA from FFPE samples [37].
The choice of the target gene mRNA is of particular
importance. It is desirable, that the target gene mRNA
is ubiquitously expressed across most cell types and that
the level of gene expression shows a similar magnitude
among the samples. We selected TBP for our multiplex
endpoint RT-PCR assay, because it was shown to be
relatively stably expressed in a range of tumour types
such as bladder cancer [24], renal cell carcinoma [25],
hepatocellular carcinoma [26], glioma [27,29] and breast
cancer [28]. TBP is expressed at moderate [27,29,38] to
low levels [23]. The choice of a highly expressed target
gene mRNA might result in an increased false negative
rate for less abundant mRNAs in gene expression stu-
dies, due to an insufficient amount of starting material
for PCR amplification. This is supported by a study,
w h i c hs h o w e dt h a to n l yal i m i t e dp r o p o r t i o no ft h e
RNA extracted from FFPE tissues is actually accessible
for cDNA synthesis [39].
We also designed our primers to avoid underlying
polymorphic sites. Target gene mRNA from highly poly-
morphic genes perhaps should be avoided. The primers
in a previous approach which used the G6PD gene actu-
ally overlie potential polymorphic sites [20]. Primer
binding sites which contain polymorphic sites will lead
to impaired or even absent PCR amplification of the
mismatched alleles.
Our multiplex endpoint RT-PCR approach utilises
random primers to synthesise cDNA. Thus after the
cDNA is assessed, the same cDNA can subsequently be
used in the final gene expression experiment(s). This
then also controls for the cDNA synthesis step.
The knowledge about which fragment sizes can be
amplified during a RT-qPCR assay helps to identify sam-
ples suitable for gene expression analysis and which
amplicon sizes can be used for an RT-qPCR assay
design. The range of PCR amplicon sizes covered by our
assay takes into account the RNA sizes normally
obtained from FFPE. The upper size range is interro-
gated by three PCR amplicon sizes (161, 252 and 300
bp), and helps to identify samples suitable for sometimes
more demanding applications, such as discrimination
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Figure 6 Spearman correlation between fragment size in the multiplex endpoint RT-PCR assay and the appropriate Cq value obtained
in the RT-qPCR assay. The x-axis shows the fragment size and the y-axis shows the Cq value. Panel A corresponds to protocol 1 (P1) and Panel
B corresponds to protocol 2 (P2).
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helps to identify samples suitable for FFPE-friendly RT-
qPCR assays which we normally design with amplicon
sizes less than 90 bp.
The good agreement between the results observed for
the multiplex endpoint RT-PCR assay and the RT-qPCR
results (Figure 6) shows that this assay can identify
FFPE samples suitable for gene expression studies. The
ten samples, which did not amplify in the multiplex
endpoint RT-PCR assay amplified all very late in the
RT-qPCR assay and would normally have been excluded
from further analysis. The 71 samples, which showed
amplification of all the amplicon sizes up to 252 bp in
the multiplex endpoint RT-PCR assay amplified with
moderate Cq values in the RT-qPCR assay and are prob-
ably the best suited samples to deliver reliable gene
expression data for most genes of interest in gene
expression analysis.
Conclusions
There is an increasing demand for the use of RNA from
FFPE both in research and in molecular diagnostic
applications such as the Oncotype DX test [6,40,41].
This is accompanied by a need for reliable methodolo-
gies to assess the quality of FFPE derived RNA. Most of
the approaches currently usedf o rR N Aq u a l i t yc o n t r o l
are not suitable or have a limited usage for the assess-
ment of such challenging material.
The validated quality control multiplex endpoint RT-
PCR assay presented here overcomes the limitations of
current approaches and is a robust method and well sui-
ted for determining the quality of a RNA preparation,
especially for FFPE derived RNA. In addition, the assay
c a nb eu s e df o rr o u t i n eq u a l i t yc o n t r o la s s e s s m e n to f
cDNA synthesis. The assay is also applicable for com-
paring or refining methodologies for RNA extraction
and cDNA synthesis. Finally, the approach is cost effec-
tive and only requires equipment which is widely
available.
Methods
Archival FFPE tissue samples
Thirty breast tumour FFPE blocks (ten each from the
years 1998, 2003 and 2008) were retrieved from the
archives of the Department of Pathology at the Peter
MacCallum Cancer Centre. The institutional ethics com-
mittee approved the study (Approval number: 03/90).
Histology procedures
The bench surface, the manual rotary microtome Leica
RM2235 (Leica Microsystems), the equipments and
glass slides were cleaned with RNaseZap (Ambion, Life
Technologies, Austin, TX) prior to use according to the
manufacturer’s directions. Diethyl pyrocarbonate
(DEPC) (Sigma, St. Louis, MO) treated water (0.1%, v/v)
was used throughout the histology procedures.
For haematoxylin and eosin (H&E) staining, a 3 μm
section from each FFPE block was stained to identify
t h et u m o u re n r i c h e da r e af o rneedle microdissection.
From each FFPE block, one to five 7 μm sections were
prepared and mounted on the glass slides. The number
of sections used in microdissection was determined by
the content of tumour cells in the tumour enriched
marked areas therefore ensuring a adequate amount of
tumour cells to be microdissected for each sample. The
content of tumour cells in all cases was assessed by a
pathologist and was in the range of 40 to 90%. After
baking the sections for five minutes on a hotplate at 70°
C, the sections were deparaffinised in three changes of
xylene for two minutes each and were taken to water by
three changes of 100% ethanol for two minutes each
and DEPC water for two minutes. Subsequently, the sec-
tions were stained with 0.5% methyl green to assist with
needle microdissection. FFPE blocks were sectioned
freshly just prior to needle microdissection and subse-
quent total RNA extraction to minimise RNA degrada-
tion after sectioning.
RNA extraction and complementary DNA (cDNA)
preparation
Two protocols were used to extract total RNA from
FFPE samples. The first protocol utilised the High Pure
FFPE RNA Micro Kit (Roche, Mannheim, Germany)
and the second protocol utilised TRIzol reagent. The
latter protocol was adapted as described from a recently
published protocol [8]. The experimental procedures
were performed in triplicates, each single experiment on
a different day.
In the first protocol referred to as protocol 1 (P1),
needle microdissected tissue from each sample was
transferred immediately to a 1.5 mL Eppendorf tube
containing 60 μL tissue lysis buffer provided by the
High Pure FFPE RNA Micro Kit. Total RNA was
extracted according to the manufacturer’sp r o t o c o l ,
eluted in 20 μL elution buffer and stored at -80°C.
In the second protocol referred to as protocol 2 (P2),
needle microdissected tissue from each sample was
immediately transferred toa1 . 5m LE p p e n d o r ft u b e
containing 260 μL of the lysis buffer from the Agen-
court FormaPure Kit (Beckman Coulter, Beverly, MA)
and incubated at 70°C for one hour. Subsequently the
tube was cooled to room temperature, 20 μL proteinase
K provided with the FormaPure Kit was added and
incubated at 55°C for one hour. The reaction mixture
was cooled to room temperature, 500 μLT R I z o l( G i b c o
BRL, Life Technologies, Grand Island, NY) and 100 μL
chloroform were added, vortexed thoroughly and incu-
bated for three minutes. After centrifugation of the tube
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layer was immediately transferred into a new 1.5 mL
Eppendorf tube. An equal volume of 2-propanol was
added to the aqueous layer, vortexed thoroughly and
incubated overnight at -20°C. The sample was centri-
fuged at 12,000g for 10 minutes at 4°C. The supernatant
was removed. The RNA pellet was washed with 1 mL
70% ethanol (4°C), vortexed thoroughly and centrifuged
at 12,000g for five minutes at 4°C. The supernatant was
removed and the 70% ethanol washing step was
repeated. The supernatant was removed again and the
R N Ap e l l e tw a sd r i e df o r1 5m i n u t e sa tr o o mt e m p e r a -
ture and resuspended in 30 μLR N a s ef r e ew a t e r .R e s i -
dual genomic DNA co-extracted with total RNA was
digested by DNase treatment employing the Turbo
DNA-Free kit (Ambion) according to the manufacturer’s
instructions in a final volume of 50 μL. The extracted
total RNA was stored at -80°C.
Total RNA concentrations were measured by the
NanoDrop ND-2000 spectrophotometer (NanoDrop
Technologies, Thermo Fisher Scientific, Wilmington,
DE) after DNase treatment for each sample derived by
each protocol in duplicate. Mean values were used to
calculate the total RNA input for cDNA synthesis. RNA
purity was estimated by the absorbance ratio A260/A280.
One hundred fifty and 75 ng respectively of total RNA
was reverse transcribed using the Superscript III Reverse
Transcriptase (Invitrogen, Life Technologies, Carlsbad,
CA) with 250 ng random hexamers (Pharmacia,
Uppsala, Sweden) according to the manufacturer’s
instructions in the presence of 20U RNase inhibitor
(Roche) in a final volume of 20 μL. The mixture was
incubated for one hour at 55°C. The resulting cDNA
was stored at -20°C.
Multiplex endpoint RT-PCR
Presence or absence of various cDNA fragments synthe-
s i z e df r o mR N Ae x t r a c t e df r o mt h eF F P Es a m p l e sw a s
determined by a multiplex endpoint RT-PCR assay
using the TBP mRNA (NM_003194) as the target
sequence (Figure 2). The assay conditions were opti-
m i s e do nac D N Am i x t u r ep r e p a r e df r o mR N A
extracted from different cell lines.
PCR was performed on the Veriti 96-well Thermal
Cycler (Applied Biosystems, Life Technologies, Foster
City, CA) in a Thermo-Fast 96 PCR Detection Plate MkII
(ABgene, Thermo Fisher Scientific, Epsom, United King-
dom) with a final reaction volume of 20 μL, containing
350 nmol/L each of the primers 92-F: 5’-GGATAAGA-
GAGCCACGAACC-3’ and 92-R: 5’-TGCCAGTCTG-
GACTGTTCTT-3’, 550 nmol/L each of the primers 161-
F: 5’-GGGCACCACTCCACTGTAT-3’ and 161-R: 5’-
CACGAAGTGCAATGGTCTTT-3’, 250 nmol/L each of
the primers 252-F: 5’-GGGAGCTGTGATGTGAAGTTT-
3’ and 252-R: 5’-TGAGAGCCATTACGTCGTCT-3’, 100
nmol/L each of the primers 300-F: 5’-GGCGGAAGTGA-
CATTATCAA-3’ and 300-R: 5’-CAGGCTGTTGTTCT-
GATCCA-3’ (GeneWorks, Adelaide, Australia), 200 μmol/
Lo fe a c hd N T P ,0 . 5 Uo fH o t S t a r T a qD N AP o l y m e r a s e
(Qiagen, Hilden, Germany) in 1× of the supplied PCR buf-
fer containing 2.5 mmol/L MgCl2 and 1 μL (if 150 ng of
total RNA was used for cDNA preparation) and 2 μL( i f
75 ng of total RNA was used for cDNA preparation) of
undiluted cDNA as template respectively. The initial dena-
turation (95°C, 15 minutes) was followed by 40 cycles of
30 seconds at 95°C, 30 seconds at 60°C and 30 seconds at
72°C, and a final extension step at 72°C for seven minutes.
Genomic DNA extracted from peripheral blood from nor-
mal individuals (2 ng/μL) was used as negative control and
a cDNA mixture prepared from total RNA of different cell
lines served as a positive control. Each sample was ana-
lysed once.
The PCR products were evaluated for band abundance
a n ds i z eb ya g a r o s eg e le l e c t rophoresis. The samples
were run on a 2% (w/v) agarose gel in a 1× TBE Buffer
system and stained with ethidium bromide. The wells
were loaded with 20 μLo ft h eP C Rp r o d u c tm i x t u r e
with 5 μL 5× loading dye. One μLp U C 1 9 / HpaII DNA
Molecular Weight Marker (GeneWorks) was run along-
side the PCR products to determine their size.
Reverse transcription - quantitative real-time PCR (RT-
qPCR)
PCR was performed on the LightCycler 480 Instrument
(Roche). Resulting data were analysed and quantified
with the LightCycler 480 software release 1.5.0 (Roche),
utilising the second derivative maximum method [42].
The calculated CP (Crossing Point) value corresponds to
the current recommended term Cq (Quantification
Cycle) value [33].
PCR was performed in LightCycler 480 Multiwell Plate
384 plates (Roche) in a final reaction volume of 10 μL
using the TBP mRNA (NM_003194) as the target
sequence (Figure 2). The TBP RT-qPCR assay was
designed and optimised as described previously [32]. 300
nmol/L of the forward primer RT-qPCR-F: 5’-GAACAT-
CATGGATCAGAACAACA-3’ and 200 nmol/L of the
reverse primer RT-qPCR-R: 5’-ATAGGGATTCCGG-
GAGTCAT-3’ (GeneWorks) were mixed in 1× LightCy-
cler 480 Probes Master (Roche) containing 100 nmol/L
of the human Universal Probe Library probe #87 (Roche),
and 1 μL (if 150 ng of total RNA was used for cDNA pre-
paration) or 2 μL (if 75 ng of total RNA was used for
cDNA preparation) of undiluted cDNA as template
respectively. The initial denaturation (95°C, 10 minutes)
was followed by 45 cycles of 10 seconds at 95°C,
30 seconds at 60°C, and a final cooling step at 40°C for
30 seconds. Each sample was analysed in duplicate.
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Statistical analyses were performed using GraphPad
Prism version 5.03 for Windows (GraphPad Software,
San Diego, CA, http://www.graphpad.com). Where
appropriate, data are presented as the mean ± standard
deviation (SD). Nonparametric correlations between a
longer amplicon size in the multiplex endpoint RT-PCR
a s s a ya n dt h ea p p r o p r i a t eC q value obtained in RT-
qPCR were evaluated by calculating the Spearman corre-
lation coefficient. A two-tailed P-value (calculated by
Gaussian approximation) of <0.05 was considered to be
statistically significant for each correlation.
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